Personalis (PSNL) to Release Earnings on Tuesday

Key Points

• Personalis is expected to release its Q2 2025 earnings on August 5th, projecting an earnings per share (EPS) of ($0.25) and revenue of $20.12 million.
• The company recently reported a prior EPS of ($0.18), exceeding analysts' expectations, with revenue of $20.61 million for the last quarter.
• Analysts maintain a consensus rating of "Buy" for Personalis, with a target price averaging $7.67.

Personalis (NASDAQ:PSNL - Get Free Report) is anticipated to release its Q2 2025 earnings data after the market closes on Tuesday, August 5th. Analysts expect Personalis to post earnings of ($0.25) per share and revenue of $20.12 million for the quarter. Personalis has set its FY 2025 guidance at EPS and its Q2 2025 guidance at EPS.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. Personalis had a negative return on equity of 48.78% and a negative net margin of 98.10%. The business had revenue of $20.61 million for the quarter, compared to analyst estimates of $17.41 million. On average, analysts expect Personalis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Personalis Stock Performance

Shares of Personalis stock traded up $0.01 during trading hours on Wednesday, reaching $5.59. 987,448 shares of the company were exchanged, compared to its average volume of 1,115,349. Personalis has a 1 year low of $2.81 and a 1 year high of $7.79. The stock's fifty day moving average is $6.03 and its 200 day moving average is $4.91. The firm has a market cap of $493.71 million, a PE ratio of -4.33 and a beta of 1.95.

Hedge Funds Weigh In On Personalis

Hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. grew its holdings in shares of Personalis by 55.7% during the first quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company's stock worth $998,000 after purchasing an additional 101,706 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company's stock worth $275,000 after buying an additional 2,395 shares during the last quarter. Dynamic Technology Lab Private Ltd grew its holdings in shares of Personalis by 75.6% during the first quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company's stock worth $269,000 after buying an additional 33,044 shares during the last quarter. Finally, Focus Partners Wealth purchased a new position in shares of Personalis during the first quarter worth about $47,000. Hedge funds and other institutional investors own 61.91% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on PSNL shares. Guggenheim started coverage on Personalis in a report on Thursday, May 15th. They issued a "buy" rating and a $6.00 target price on the stock. HC Wainwright raised their price objective on Personalis from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, May 7th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $7.00 price objective on shares of Personalis in a report on Thursday, April 10th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Personalis currently has a consensus rating of "Buy" and a consensus price target of $7.67.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.